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Summary 
The effect of lead on two calcium sensitive processes was deter- 
mined. Micromolar concentrations of lead successfully replaced 
calcium in the activation of calmodulin-sensitive phosphodiesterase 
and in the promotion of potassium loss from erythrocytes. Both 
actions of lead were blocked by trifluoperazine--an inhibitor of 
calmodulin function. We propose that some of the toxic effects of 
lead may be explained by its interaction with calmodulin. 
Children poisoned with lead may develop brain injury, muscle weakness, 
anemia, and renal tubular dysfunction (I). It is well established that 
calcium influences the absorption and distribution of lead (2), but this 
observation does not explain the cellular manifestations of lead toxicity. To 
determine whether lead might alter cell function by substituting for calcium 
in regulatory processes, we measured the effect of lead upon the activity of 
two calcium-sensitive reactions. We found that lead could replace calcium in 
the calmodulin-dependent activation of cyclic nucleotide phosphodiesterase 
(PDE) and in the promotion of potassium efflux from erythrocytes. Both 
effects were blocked by trifluoperazine (TFP), an inhibitor of calmodulin 
action. 
Materials and Methods 
The activator deficient PDE and calmodulin used in these experiments were 
purchased from Sigma Chemical, St. Louis, MO. PDE activity was determined by 
measuring conversion of cAMP to adenosine (3). The reaction mixture contained 
700 ~ units of bovine heart, activator-deficient PDE with or without 200 ng of 
phosphodiestera~e 3':5'-cyclic nucleotide activator (calmodulin), 20 ~M cAMP, 
and 0.i ~Ci of H-cAMP in a total volume of i00 ~I calcium-free buffer (i00 mM 
Tris, pH 8.0, 1 mM MgSO,, 600 ~M dithiothreitol, and i0 ~M EGTA). The EGTA 
was added to chelate endogenous calcium. The concentration of lead chloride 
in the incubation varied from 0 to i00 ~M. To inhibit calmodulin binding to 
PDE, 20 ~M TFP was added when the lead concentration was 50 ~M. 
The effect of calcium, lead and calmodulin on potassium permeability was 
studied with red blood cells. Human red blood cells were prepared from fresh 
heparized blood, washed three times in 20 volumes of ice cold 15 mM HEPES 
buffered saline, pH 7.4, containing 2 mM CaCI~. A cell pellet was prepared by 
centrifuging red blood cells at 600 x g for 16 min and then resuspended in 
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3 volumes of ice cold buffer. Incubations were initiated by adding 200 ~i of 
the red blood cell suspension to 4.8 ml of buffer prewarmed to 37°C. Calcium 
entry into the cells was produced with the specific calcium ionophore, A23187. 
The ionophore was dissolved in DMSO and added to the incubation at time zero 
in a volume of 5 ~i. The final concentration of A23187 was 0.2 ~g/ml. DMSO 
alone had no effect on potassium release. To chelate calcium, the cells were 
preincubated I0 min at 37°C in S mM EGTA. When present, lead chloride was 
added to the incubation at time zero at a final concentration of i0 ~M. To 
inhibit calmodulin action the cells were preincubated 5 min with 20 ~M TFP at 
37°C. The reaction was stopped with 5 ml of ice cold buffer and centrifuga- 
tion for I0 min at 600 x g. The concentration of potassium in the supernatant 
was measured using a flame photometer. 
Results and Discussion 
The role of calmodulin, an intracellular calcium receptor protein, in the 
regulation of several enzymes and transport systems, has only recently been 
discovered and the list of calcium-sensitive reactions modulated by the 
calmodulin-calcium complex is rapidly expanding (4, 5). When the concentra- 
tion of calcium in the cytosol rises, calcium ions bind to high affinity sites 
on calmodulin causing the configuration of the protein to change (6). The 
complex is then able to alter the activity of certain enzymes and transport 
systems. TFP inhibits this cascade by binding to the calmodulin-calcium 
complex and preventing its interaction with calcium-sensitive enzymes (7). 
Since lead is known to have a kinetic behavior similar to calcium in intact 
cells (8) and to compete with calcium for absorption from the intestine (9), 
incorporation into bone (i0), and accumulation by mitochondria (Ii, 12), we 
questioned whether lead could replace calcium in the activation of calmodulin. 
Figure 1 shows the stimulation of PDE by calmodulin and lead. The 
incubation buffer has no'added calcium and contains i0 ~M EGTA to remove endo- 
genous calcium. PDE activity increased when the concentration of lead exceed- 
ed that of EGTA, a finding explained by the capacity of EGTA to bind lead on 
an equimolar basis. The stimulation of PDE by calmodulin and lead was 
inhibited more than 50% by 20 ~M TFP. This is consistent with observations 
that TFP blocks calmodulin-calcium activation of PDE with an I5n of i0 ~M (7). 
Lead had no effect on the activity of PDE in the absence of carmodulin. When 
PDE was maximally activated by calmodulin and either lead or calcium, addition 
of the other divalent cation did not change the activity of the enzyme (exper- 
iments not shown). From these results we cannot determine the mechanism by 
which lead activates PDE in the presence of calmodulin, but since+divalent 
++ ++ ++ Zn ++ cations in addition to calcium (i.e., Sr , Ni , Co , , Mn but not 
Ba ++ or Mg ++) support the binding of TFP to calmodulin (13), we suspect that 
lead is acting directly at the high affinity calcium binding sites on 
calmodulin. 
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FIG. 1 
Effect of increasing lead concentration upon PDE. Enzyme activity 
was measured in the presence (O) or absence (O) of added cal- 
modulin. To inhibit calmodulin binding, 20 ~M TFP was added (~) 
when the lead concentration was 50 ~M. Incubations were performed 
in triplicate and results are expressed as the fold-stimulation of 
PDE + S.D. The basal activity of PDE was 180 pmol adenosine formed 
per TO min. Where not shown, the deviations were less than 5% of 
the mean. Stimulation of PDE by lead required the presence of 
calmodulin and was inhibited by TFP. 
If lead functions as a calcium agonist in the activation of calmodulin, 
it should alter calmodulin dependent cell functions that normally respond to 
changes in the cytosol concentration of ionized calcium. By either energy 
depleting erythrocytes or treating them with a calcium specific ionophore, 
A23187, it is possible to raise their cytosolic concentration of calcium (14). 
One response to such an elevation is a marked increase in the permeability of 
the cell membrane to potassium (15). The effect is selective and not 
associated with loss of intracellular sodium. We found that potassium loss 
produced in this fashion was largely prevented by preincubating the red blood 
cells for 5 minutes with 20 ~M TFP (Fig. 2). This is the same concentration 
of TFP that inhibits calmodulin activation of calcium regulated enzymes (7). 
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FIG. 2 
Effect of TFP on the release of potassium from human red blood cells 
treated with calcium ionophore, A23187. Incubations were performed 
in the presence of 0.2 ~g/ml ionophore alone (Q), ionophore with 
l0 ~M EGTA (A), ionophore with 20 ~M TFP (I), EGTA alone (A), 
or TFP alone ([]). The results are averages of three determina- 
tions + S.D. Where not sho~n, the deviations were less than 5% of 
the mean. The release of K promoted by the calcium ionophore, 
A23187, was inhibited by TFP. In addition, it was largely prevented 
by chelation of calcium with EGTA prior to addition of the ionophore. 
Although TFP has effects in addition to calmodulin blockade, other biologic 
events which are inhibited by micromolar concentrations of TFP have been 
assumed to be mediated by calmodulin (5, 16). Thus, this observation 
implicates calmodulin in the regulation of potassium permeability by the 
cytosolic concentration of calcium in red blood cells. Exposing red blood 
cells to lead also rapidly leads to selective potassium loss (17). Unlike the 
calcium effect, there is no need to energy deplete the cells or add an iono- 
phore since lead readily enters red blood cells. We found that the same 20 ~M 
concentration of TFP that inhibited the loss of potassium from red blood cells 
with a raised calcium concentration (Fig. 2) also prevented the loss of 
potassium from red blood cells exposed to lead (Fig. 3). These findings 
suggest that both calcium and lead produce potassium loss from erythrocytes by 
activating calmodulin. The possible significance of this observation to lead 
poisoning is supported by the similarity between the threshhold for the lead- 
induced permeability change in erythrocytes (5-10 ~M) and the concentration of 
lead in the blood of children with symptoms of lead poisoning (18). 
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FIG. 3 
Effect of TFP on the release of potassium from human red blood cells 
treated with lead. Incubations were performed in the presence of 
i0 ~M lead (O), lead with 20 ~M TFP (S) or TFP alone (D). The 
results are averages of three determinations ~ S.D. Where not ~hown, 
the deviations were less than 5% of the mean. The release of K 
promoted by lead was blocked by TFP. 
In a study of heavy metal interaction with.cyclic nucleotide metabolism, 
Nathanson and Bloom described a marked inhibition of adenyl cyclase by lead 
and other heavy metals (19). Competition at the calmodulin binding site seems 
unlikely for this effect since high concentrations of calcium d~d not reverse 
the inhibition. In addition, they observed a 22% stimulation of PDE by lead 
while other heavy metals were without effect. The relation of calcium and 
calmodulin to the stimulation of PDE by lead was not investigated. 
We found that lead can replace calcium in the activation of calmodulin- 
sensitive PDE and in the promotion of potassium loss from red blood cells. 
Both processes were inhibited by low concentrations of TFP. Taken together, 
these observations support a molecular model for lead toxicity in which lead 
alters the function of a tissue by entering the cell and occupying calcium 
binding sites on calmodulin. Since calmodulin regulates multiple cell 
activities and is present in virtually all tissues, this mechanism may 
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underlie some of the diverse effects of lead poisoning. Tissue differences in 
lead permeability, calmodulin concentration, calmodulin-sensitive functions, 
and internal calcium concentration might explain in part the different 
thresholds and responses of various organs to the toxic effects of lead. 
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